Study confirms efficacy of Regeneron's antibody drug

Wednesday, 16. June 2021 11:58

Regeneron Pharmaceuticals's antibody treatment REGEN-COV is improving the survival rate in hospitalized COVID-19 patients who haven't established their own immune response by as much as 20%, according to study results published on Wednesday.

"The hope was that by giving a combination of antibodies targeting the SARS-CoV-2 virus we would be able to reduce the worst manifestations of COVID-19," Oxford University Professor Peter Horby noted, adding that "it is wonderful to learn that even in advanced COVID-19 disease, targeting the virus can reduce mortality in patients who have failed to mount an antibody response of their own."

The American biotech company added it will now work with regulatory authorities in the United States on expanding emergency use authorization so it includes hospitalized patients.

Related Links: Regeneron Pharmaceuticals Inc.
Breaking the News / ND